CCT244747
| Code | Size | Price |
|---|
| SYN-1216-M050 | 50 mg | Enquire |
Quantity:
| SYN-1216-M001 | 1 mg | £115.00 |
Quantity:
| SYN-1216-M005 | 5 mg | £233.00 |
Quantity:
| SYN-1216-M010 | 10 mg | £350.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
Short Term: +4°C, Long Term: +4°C
Documents
Further Information
Alternate Names/Synonyms:
(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile
Appearance:
Solid.
CAS:
1404095-34-6
EClass:
32160000
Form (Short):
liquid
Hazards:
H303, H317, H333
InChi:
InChI=1S/C20H24N8O2/c1-13(11-27(2)3)30-20-16(7-21)22-10-19(26-20)25-18-6-17(29-5)15(9-23-18)14-8-24-28(4)12-14/h6,8-10,12-13H,11H2,1-5H3,(H,23,25,26)/t13-/m1/s1
InChiKey:
IENLGMOXAQMNEH-CYBMUJFWSA-N
Long Description:
Chemical. CAS: 1404095-34-6. Formula: C20H24N8O2. MW: 408.5. CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC50 of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.
Molecular Formula:
C20H24N8O2
Molecular Weight:
408.5
Package Type:
Plastic Vial
Product Description:
CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC50 of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors: M. Lainchbury, et al.; J. Med. Chem. 55, 10229 (2012) | CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs: M.I. Walton, et al.; Clin. Cancer Res. 18, 5650 (2012) | The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment: I. Patties, et al.; J. Exp. Clin. Cancer Res. 38, 420 (2019)